Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

N/A

3(42.9%)

7Total

Phase 2(4)

N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02658578Not ApplicableCompleted

Peripheral Nerve Stimulation and Motor Training in Stroke

Role: collaborator

NCT03021200Not ApplicableUnknown

Laser Fluorescence in Cancer Surgical Treatment

Role: collaborator

NCT01370239Phase 2Terminated

HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy

Role: collaborator

NCT01907737Not ApplicableCompleted

Combined Brain and Peripheral Nerve Stimulation for Stroke

Role: collaborator

NCT01329627Phase 2Terminated

Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer

Role: collaborator

NCT01168505Phase 2Unknown

Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients

Role: collaborator

NCT01329640Phase 2Terminated

Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)

Role: collaborator

All 7 trials loaded